{
}
GSK reported a strong fiscal year with a 7% increase in currency-adjusted revenue, reaching £31 billion, driven by growth in cancer treatments and innovative medicines. The company raised its sales targets to 2031 and announced a £2 billion share buyback over the next 18 months. Analysts have varied ratings for GSK, with Bernstein maintaining an 'Outperform' at a target of 2355 pence, while Deutsche Bank holds a 'Hold' rating with a target of 1450 pence.
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
GSK's RSV vaccine, Arexvy, demonstrated 63% overall efficacy and 67% against severe disease over three seasons, though effectiveness declined to 48% in the third season. The CDC currently does not recommend a second dose, but GSK anticipates that revaccination may be necessary to maintain protection. The findings will be presented at the CHEST 2024 Annual Meeting.
Peter Welford
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
gsk reports strong year-end results and raises sales targets to 2031
British Pound Sterling
Glaxosmithkline plc
CHN
USA
GBR
James Gordon
Luisa Hector
Emmanuel Papadakis
Peter Welford
Rajan Sharma
Florent Cespedes
Show more
07:14 06.02.2025
novo nordisk faces stock plunge after disappointing results for obesity drug
Danish Krone
Catalent, Inc.
Novo Nordisk A/S
Eli Lilly and Company
DNK
Florent Cespedes
Emmanuel Papadakis
Jo Walton
Peter Welford
Show more
15:35 20.12.2024
GSK RSV vaccine shows effectiveness over three seasons but wanes over time
14:15 08.10.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Financial Scams and Security
Global Financial Events
Market Analysis and Predictions
Hedge Funds & Private Equity
Retail and Consumer Goods
Supply Chain Management
Startups & Entrepreneurship
CEO Changes
Workplace Trends
Global Trade Developments
Cryptocurrency Trends
Government Economic Policies
Venture Capital Investments
Real Estate Investments
Crypto Adoption and Integration
Countries:
Companies:
JPMorgan Chase & Co.
Barclays PLC
Bank of America Corporation
The Goldman Sachs Group, Inc.
Citigroup Inc.
Tesla, Inc.
Geode Capital Management LLC
Morgan Stanley
The Charles Schwab Corporation
Wells Fargo & Company
NVIDIA Corporation
Credit Suisse Real Estate Fund Siat
Charles Schwab Investment Management Inc.
State Street Corporation
Broadcom Inc.
Deutsche Bank Aktiengesellschaft
Apple Inc.
Tesmec S.p.A.
Lloyds Banking Group plc
HSBC Holdings plc
Currencies:
United States Dollar
Swiss Franc
British Pound Sterling
Chinese Yuan
Euro
Indian Rupee
United Arab Emirates Dirham
South Korean Won
Offshore Chinese Yuan
Japanese Yen
Azerbaijani Manat
New Taiwan Dollar
Saudi Riyal
Singapore Dollar
Vietnamese Đồng
People: